Noile-Immune Biotech (4893), Earnings Report: Operating Loss of 419 Million Yen

Noile-Immune Biotech (4893) has released its financial results, reporting an operating loss of 419 million yen, an ordinary loss of 370 million yen, and a net loss of 372 million yen, with a net loss per share of 8.59 yen. The results reflect the ongoing upfront investments in research and development typical for a clinical-stage biotechnology company.

Despite the recurring operational losses and a retained earnings balance of -4.15 billion yen—reflecting past R&D investments—the company maintains an exceptionally robust financial foundation. The equity ratio stands at a high 97.3%, with zero interest-bearing debt, and cash and cash equivalents of 3.54 billion yen. The company's solid capital structure provides a strong cushion while advancing its pipeline toward future commercialization.